HSD17B11
Estradiol 17-beta-dehydrogenase 11
Protein Summary
Can convert androstan-3-alpha,17-beta-diol (3-alpha-diol) to androsterone in vitro, suggesting that it may participate in androgen metabolism during steroidogenesis. May act by metabolizing compounds that stimulate steroid synthesis and/or by generating metabolites that inhibit it. Has no activity toward DHEA (dehydroepiandrosterone), or A-dione (4-androste-3,17-dione), and only a slight activity toward testosterone to A-dione. Tumor-associated antigen in cutaneous T-cell lymphoma. Short-chain alcohol dehydrogenases, such as HSD17B11, metabolize secondary alcohols and ketones (Brereton et al., 2001 [PubMed 11165019]).[supplied by OMIM, Jun 2009]
- ENST00000358290
- ENSP00000351035
- ENSG00000198189
- DHRS8
- PAN1B
- SDR16C2
- DHRS8
- PAN1B
- RETSDR2
- SDR16C2
- 17BHSD11
- 17-BETA-HSD11
- 17-BETA-HSDXI
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
PubMedID | 0.86 | ||
small molecule perturbation | 0.83 | ||
transcription factor binding site profile | 0.8 | ||
gene perturbation | 0.74 | ||
tissue sample | 0.71 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 18.74 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 179 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 18.74 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 179 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 4
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0